

type of report	Current report
number	58/2014
company	Pharmena Spółka Akcyjna

#### **Decision on granting a patent in USA**

The Management Board of PHARMENA S.A. declares that on 8<sup>th</sup> November 2014 it received notification that US Patent Office decided on granting a patent to patent application no. US13/083,106 concerning the use of 1-methylnicotinamide (1-MNA) in atherosclerosis treatment, related to 1-MNA's ability to increase the level of prostacyclin. The patent ensures the Company a patent protection in the abovementioned scope in USA.

This is yet another patent (previous ones were granted among others in USA, Europe, Russia, Mexico, Canada, Australia, and China) which the Company receives within patent applications concerning the use of selected pyridinium salts in vascular protection, as in the previous years, the Company made a vast number of patent applications to ensure a worldwide protection.

The information is made public due to the fact that it may influence the asset valuation of PHARMENA S.A. in the form of patents and patent applications for the use of active substances which PHARMENA S.A. possesses rights to, as well as because of participation in potential revenue resulting from commercialisation of the aforementioned patents and patent applications.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

#### **Representatives of the company:**

- Konrad Palka - President of the Board
- Marzena Wieczorkowska - Vice President of the Board